His early discovery that GLP-1 stimulates insulin secretion in a glucose-dependent manner paved the way for today's widely popular medications for type 2 diabetes and obesity.
Our discovery of GLP-1 as a satiety hormone was patented in collaboration with the pharmaceutical company Novo Nordisk A/S in November 1996 [7] (I receive no royalty or other payments).
Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone.
As Director of the Metabolism & Body Composition Laboratory, one of Dr. Heymsfields key contributions is his involvement in the discovery and development of GLP-1 receptor agonists, a class of drugs that have become a major breakthrough in obesity treatment.
Furthermore, visual representations like the one above help us fully grasp the concept of His Early Discovery That Glp.
In the 1980s, his laboratorys gene cloning efforts revealed that the gene encoding glucagon also contained sequences for related hormones, which were later identified as GLP-1 and GLP-2.
His start-up, Medvi, a telehealth provider of GLP-1 weight-loss drugs, got 300 customers in its first month. In its second month, it gained 1,000 more. In 2025, Medvis first full year in business, the company generated $401 million in sales.
